I think Merck will end up taking it to market. CG0070 is currently paired with Keytruda in a phase 2 trial
Personally, I think some of the cash will be used to in-licence Nuray Chemicals patent for Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof. Pfizer's VYNDAQEL franchise brought $686 million last quarter . I see Novitium filing a505(b)(2) as a possibility. After all Samy Shanmugam was the lead inventor in the patent which is set to expire in November 2041.